Aethlon Medical Inc., a company specializing in medical therapeutics for cancer and infectious diseases, has announced the acceptance of an abstract for a poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes. The presentation will focus on new pre-clinical data regarding the Hemopurifier®, an investigational extracorporeal device designed to bind and remove harmful extracellular vesicles (EVs) from the blood. The data examines the device's ability to bind mannosylated EVs found in individuals with Long COVID. The presentation, led by Dr. Steven P. LaRosa, Chief Medical Officer of Aethlon Medical, will take place on August 12, 2025, at 19:30 MDT in Santa Fe, NM. Results have not yet been presented but will be available on the Aethlon Medical corporate website after the symposium.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.